Company
Monte Rosa Therapeutics, Inc.
Degrading Proteins, Making Medicines
Also known as Monte Rosa Therapeutics
- Status
- IPOas of 2026-09-20Source (opens in a new tab)
- Business model
- B2B
- Headquarters
- Boston, MA, United States
- Founded
- 2018
- monterosatx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
At Monte Rosa, our team of scientists is working together to rapidly advance MGD programs that target undruggable or inadequately drugged targets with unprecedented specificity.
Funding snapshot
- Total raised
- $143MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $95M2021-03-11
Funding rounds
- Round, 2021
- $95M2021-03-11, SEC form D sold, 23 investors
- Round, 2020
- $48M2020-09-14, SEC form D sold, 17 investors
About the company
- Status notes
- Monte Rosa goes public with the ticker GLUE
Loading relationship preview